Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
Chemomab Therapeutics (CMMB) announced the successful completion of its End-of-Phase 2 Meeting with the FDA and alignment with FDA on the ...
Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month ...
Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of ...
4h
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Topline results for COAST are anticipated in early Q2 2025, with ShORe results expected mid-2025.
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback